Crohn’s disease (also known as regional enteritis) is a chronic, episodic, inflammatory condition of the gastrointestinal tract characterized by transmural inflammation (affecting the entire wall of the involved bowel) and skip lesions (areas of inflammation with areas of normal lining in between).
Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn’s Disease – Cimzia (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) for reducing signs and symptoms of Crohn’s disease is now available for self-administration in a prefilled syringe.
This international research study, published in The Lancet, has thrown into question the current method of treating Crohn’s disease ? opening the door to a safer and more effective treatment option for sufferers of the chronic disease. – A new study established the new alternative strategy, called “top-down” therapy, to treat the patients with Crohn’s disease by employing early use of immune-suppressing drugs combined with an antibody without using steroids.
Mycobacterium paratuberculosis found in cows milk may cause Crohn’s disease in humans, revealed by researchers at the University of Liverpool, UK.
– Researchers at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn’s disease in humans. Crohn’s is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.
